Study OEV-120 – Phase I, Safety and immunogenicity of a prototype vaccine
The safety and immunogenicity of a prototype vaccine was compared to a previously developed oral ETEC vaccine in a randomized clinical Phase I trial in 59 Swedish volunteers. The volunteers were given two oral doses of either the prototype or the reference vaccine. The prototype vaccine was found to be as safe and equally well tolerated as the reference vaccine.
Studies
- All studies
-
Study OEV-128 – Phase IIB Study in children 6-18 months in The Gambia
-
Study OEV-124 – Phase I, Age-descending study in Zambia
-
Study OEV-123 – Phase IIb Safety, diagnostic methodology evaluation and estimated vaccine efficacy in travellers to Benin
-
Study OEV-122 – Phase I/II, Age descending safety and immunogenicity trial in Bangladesh (age ≥6 mo)
-
Study OEV-121A – Phase I, Booster dose memory study
-
Study OEV-121 – Phase I, Safety and immunogenicity of vaccine
-
Study OEV-120 – Phase I, Safety and immunogenicity of a prototype vaccine
-
Study DMID 09-066 – Phase I, dmLT adjuvant safety and immunogenicity
-
